Physician profile
William Sanderson
NPI 1164407136
$7,402.23
in general payments reported to CMS, 2019-2025
37 companies · $2,042 in 2025
The $2,042 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $998 · 2020: $341 · 2021: $761 · 2022: $846 · 2023: $909 · 2024: $1,506 · 2025: $2,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,005 · Travel and Lodging: $252 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,005.17 |
| Travel and Lodging | $251.54 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,651.41 | 2019-2025 | Erleada, Akeega, Carvykti |
| Astellas Pharma US INC | $1,042.88 | 2019-2025 | Xtandi |
| Sumitomo Pharma America, INC. | $777.77 | 2023-2025 | Gemtesa, Orgovyx |
| Dendreon Pharmaceuticals LLC | $675.83 | 2019-2025 | Provenge |
| Procept Biorobotics Corporation | $619.74 | 2024-2025 | Aquabeam System |
| Pfizer INC. | $357.82 | 2019-2025 | |
| Coloplast Corp | $243.71 | 2019-2025 | |
| Urogen Pharma, INC. | $234.46 | 2021-2025 | |
| Endo USA, INC. | $198.17 | 2024-2025 | Xiaflex, Aveed |
| Endo Pharmaceuticals INC. | $195.16 | 2019-2024 | Aveed, Xiaflex, Edex |
| Myovant Sciences INC. | $129.75 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $129.53 | 2023-2025 | |
| Abbvie INC. | $122.79 | 2019-2023 | Botox |
| Myriad Genetic Laboratories, INC. | $121.70 | 2023-2025 | Prolaris, Myrisk |
| Novartis Pharmaceuticals Corporation | $113.80 | 2024-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $101.35 | 2022 | |
| Immunitybio, INC. | $97.89 | 2025 | |
| Olympus America INC. | $80.96 | 2023-2025 | Itind System, Gyrus Acmi |
| Allergan, INC. | $68.68 | 2019-2022 | |
| Tolmar, INC. | $55.27 | 2024-2025 | Jatenzo, Eligard |
| 180 Medical, INC. | $53.91 | 2024 | Gentlecath Glide, Gentlecath |
| Baxter Healthcare | $41.14 | 2021 | |
| Progenics Pharmaceuticals, INC. | $37.66 | 2023 | Pylarify |
| Boston Scientific Corporation | $35.55 | 2019-2021 | |
| Convatec INC. | $25.48 | 2024 | |
| Blue Earth Diagnostics | $24.95 | 2022 | |
| Antares Pharma, INC. | $24.65 | 2023 | Tlando, Xyosted, Nocdurna |
| Ferring Pharmaceuticals INC. | $20.44 | 2024 | Adstiladrin |
| Merck Sharp & Dohme LLC | $19.61 | 2021 | |
| Accord Healthcare, INC. | $17.01 | 2023 | |
| Mission Pharmacal Company | $16.96 | 2024 | Uribel Tabs |
| Telix Pharmaceuticals | $15.91 | 2024 | Illuccix |
| Cycle Pharmaceuticals INC | $15.49 | 2025 | Venxxiva |
| Bioprotect Medical, INC. | $14.05 | 2025 | Bioprotect Balloon Implant System |
| Ethicon US, LLC | $12.21 | 2021 | |
| Janssen Pharmaceuticals, INC | $8.54 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Sanderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.